Portal de Periódicos da CAPES

Decreased PLK1 expression denotes therapy resistance and unfavourable disease-free survival in rectal cancer patients receiving neoadjuvant chemoradiotherapy

2016; Elsevier BV; Volume: 212; Issue: 12 Linguagem: Inglês

10.1016/j.prp.2016.09.012

1618-0631

Arancha Cebrián, Teresa Gómez del Pulgar, María Jesús Fernández‐Aceñero, Aurea Borrero‐Palacios, Laura del Puerto‐Nevado, Javier Martínez‐Useros, Juan Pablo Marín‐Arango, Cristina Caramés, R. Vega-Bravo, María Rodríguez‐Remírez, Félix Manzarbeitia, Jesús García‐Foncillas,

Colorectal Cancer Treatments and Studies

Polo-like kinase 1 (Plk1) plays a key role in mitotic cell division and DNA damage repair. It has been observed that either up-regulated or down-regulated Plk1 could induce mitotic defects that results in aneuploidy and tumorigenesis, probably depending on the context. Few previous reports have associated Plk1 expression with prognosis and response to radiotherapy in rectal carcinomas. The aim of this study is to investigate the prognostic impact of Plk1 expression and its role in predicting response to neoadjuvant cheomoradiotherapy in rectal cancer. Immunohistochemical analysis of Plk1 expression was performed in the pre-treatment tumour specimens from 75 rectal cancer patients. We analysed the assocation between Plk1 expression and clinicopathological parameters, pathologic response and outcome. Opposed to previous reports on this issue, low expression of Plk1 was significantly associated with a high grade of differentiation (P = 0.0007) and higher rate of distant metastasis (P = 0.014). More importantly, decreased levels of Plk1 were associated with absence of response after neoadjuvant therapy (P = 0.049). Moreover, low Plk1 expression emerged as an unfavourable prognostic factor for disease-free survival in the non-responder group of patients (P = 0.037). Decreased Plk1 expression was associated with poor pathologic response and worse disease-free survival in rectal cancer patients receiving neoadjuvant chemoradiotherapy, suggesting Plk1 as a clinically relevant marker to predict chemoradiotherapy response and outcome.